Corbus Pharmaceuticals Announces Abstract Accepted For Presentation At 2024 ASCO GU
Portfolio Pulse from Benzinga Newsdesk
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) has announced that its partner CSPC's Phase 1 clinical data for CRB-701 (SYS6002) will be presented at the 2024 ASCO GU Symposium. CRB-701 is a next-generation ADC targeting nectin-4, differentiated from the FDA-approved PADCEV®. The presentation will cover the dose escalation study conducted in China and pre-clinical data that was shared at the 2023 AACR-NCI-EORTC conference.
December 18, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corbus Pharmaceuticals' partner CSPC's Phase 1 clinical data for CRB-701 will be presented at the 2024 ASCO GU, potentially enhancing the company's profile in precision oncology.
The acceptance of CRB-701's clinical data for presentation at a prestigious conference like ASCO GU is likely to be viewed positively by investors and could increase visibility and credibility of Corbus' oncology portfolio. This may lead to a short-term positive impact on the stock price as the market reacts to potential advancements in the company's pipeline.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90